Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus GLOFIL 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus GLOFIL 125.
AMMONIA N 13 vs GLOFIL-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
GLOFIL-125 (pentoxifylline) is a xanthine derivative that improves erythrocyte flexibility by inhibiting phosphodiesterase, leading to increased intracellular cAMP. It also reduces blood viscosity and platelet aggregation, improving microcirculation.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
125 mg orally twice daily.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal elimination half-life: 2.5–3.5 hours (prolonged in renal impairment; up to 20–30 hours in severe chronic kidney disease).
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Renal excretion of unchanged drug >90%; biliary/fecal <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical